Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CT1390B in Relapsing acute myeloid leukemia: NCT07617285 Clinical Landscape Report 2026
16 September 2026
NCT07617285 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Decitabine in Acute Myeloid Leukemia: NCT07617363 Clinical Landscape Report 2026
16 September 2026
NCT07617363 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
IASO 207 in Systemic Lupus Erythematosus: NCT07617740 Clinical Landscape Report 2026
16 September 2026
NCT07617740 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KSVCBD (Chinese People's Liberation Army General Hospital) in High grade B-cell lymphoma: NCT07620314 Clinical Landscape Report 2026
16 September 2026
NCT07620314 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludeoxyglucose F-18 in Melanoma, Cutaneous Malignant: NCT07621614 Clinical Landscape Report 2026
16 September 2026
NCT07621614 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Florbetaben F-18 in Monoclonal Gammopathy of Undetermined Significance: NCT07624760 Clinical Landscape Report 2026
16 September 2026
NCT07624760 clinical landscape for Monoclonal Gammopathy of Undetermined Significance: endpoints, sponsor, phase, geography, readouts, asset context and deve…
9 min read
KSVCBD (Chinese People's Liberation Army General Hospital) in Multiple Myeloma: NCT07620275 Clinical Landscape Report 2026
16 September 2026
NCT07620275 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
JLM019 in Hodgkin's Lymphoma: NCT07623850 Clinical Landscape Report 2026
16 September 2026
NCT07623850 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HH160 in Hepatocellular Carcinoma: NCT07623369 Clinical Landscape Report 2026
16 September 2026
NCT07623369 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DQ1001 in Relapse multiple myeloma: NCT07622862 Clinical Landscape Report 2026
16 September 2026
NCT07622862 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Bladder Cancer: CTRI/2026/06/111963 Clinical Landscape Report 2026
16 September 2026
CTRI/2026/06/111963 clinical landscape for Bladder Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mifamurtide in Triple Negative Breast Cancer: NCT07622836 Clinical Landscape Report 2026
16 September 2026
NCT07622836 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.